Kosin Medical Journal (고신대학교 의과대학 학술지)

Kosin University College of Medicine (고신대학교 의과대학)
권호 표지
DOI QR코드

DOI QR Code

Fludarabine and Rituximab in Relapsed or Refractory Hairy Cell Leukmia Variant: A Case Report and Review of Literature

  • Lee, Ji Won (Departments of Internal medicine, Laboratory medicine, Veterans Health Service Medical Center) ;
  • Choi, Youn Mi (Departments of Laboratory medicine, Veterans Health Service Medical Center) ;
  • Yang, Jae Yun (Departments of Internal medicine, Laboratory medicine, Veterans Health Service Medical Center) ;
  • Han, Seung Moon (Departments of Internal medicine, Laboratory medicine, Veterans Health Service Medical Center) ;
  • Kim, Bong Seog (Departments of Internal medicine, Laboratory medicine, Veterans Health Service Medical Center) ;
  • Nam, Seung-Hyun (Departments of Internal medicine, Laboratory medicine, Veterans Health Service Medical Center)
  • Received : 2016.08.10
  • Accepted : 2016.09.21
  • Published : 2018.12.31
⟨ Previous Next ⟩

Abstract

Hairy cell leukemia (HCL) is a rare chronic B cell leukemia morphologically characterized by cells with an abundant cytoplasm and hair-like projections that can be found in the peripheral blood and bone marrow. The treatment for HCL is splenectomy or chemotherapy with the purine analogs pentostatin and cladribine. However, patients continue to relapse. Retreatment with the same or alternate purine analogs produces lower response rates and a shorter duration of response. Fludarabine is another purine analog widely used in treating indolent lymphoid cancers, often in combination with rituximab. Here, we report a case of HCL variant in a 60-year-old man who experienced multiple relapses after splenectomy and retreatment with cladribine. The patient was then treated with fludarabine and rituximab combination chemotherapy. After the treatment, he achieved complete remission that continued for 35 months.

Keywords

References

  1. Gerrie AS, Zypchen LN, Connors JM. Fludarabine and rituximab for relapsed or refractory hairy cell leukemia. Blood 2012;119:1988-91. https://doi.org/10.1182/blood-2011-08-371989
  2. Else M, Dearden CE, Matutes E, Garcia-Talavera J, Rohatiner AZ, Johnson SA, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009;145:733-40. https://doi.org/10.1111/j.1365-2141.2009.07668.x
  3. Sgarabotto D, Vianello F, Radossi P, Poletti A, Sotti G, Stefani PM, et al. Remission in hairy cell leukemia-variant following splenic radiotherapy alone. Leuk Lymphoma 1997;26:395-8. https://doi.org/10.3109/10428199709051790
  4. Golomb HM, Vardiman JW. Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement. Blood 1983;61:349-52. https://doi.org/10.1182/blood.V61.2.349.349
  5. Magee MJ, McKenzie S, Filippa DA, Arlin ZA, Gee TS, Clarkson BD. Hairy cell leukemia. Durability of response to splenectomy in 26 patients and treatment of relapse with androgens in six patients. Cancer 1985;56:2557-62. https://doi.org/10.1002/1097-0142(19851201)56:11<2557::AID-CNCR2820561103>3.0.CO;2-T
  6. Habermann TM, Rai K. Historical treatments of in hairy cell leukemia, splenectomy and interferon: past and current uses. Leuk Lymphoma 2011;52:18-20. https://doi.org/10.3109/10428194.2011.573033
  7. Maevis V, Mey U, Schmidt-Wolf G, Schmidt-Wolf IG. Hairy cell leukemia: short review, today's recommendations and outlook. Blood Cancer J 2014;4:e184. https://doi.org/10.1038/bcj.2014.3
  8. Robak T. Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Cancer Treat Rev 2006;32:365-76. https://doi.org/10.1016/j.ctrv.2006.04.010
  9. Johnston JB. Mechanism of action of pentostatin and cladribine in hairy cell leukemia. Leuk Lymphoma 2011;52:43-5. https://doi.org/10.3109/10428194.2011.570394
  10. Almasri NM, Duque RE, Iturraspe J, Everett E, Braylan RC. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol. 1992;40:259-63. https://doi.org/10.1002/ajh.2830400404
  11. Robbins BA, Ellison DJ, Spinosa JC, Carey CA, Lukes RJ, Poppema S, et al. Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood 1993;82:1277-87. https://doi.org/10.1182/blood.V82.4.1277.1277
  12. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45. https://doi.org/10.1182/blood.V83.2.435.435
  13. Kreitman RJ, Arons E, Stetler-Stevenson M, Fitzgerald DJ, Wilson WH, Pastan I. Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia. Leuk Lymphoma 2011;52:82-6. https://doi.org/10.3109/10428194.2011.565843
  14. Jones G, Parry-Jones N, Wilkins B, Else M, Catovsky D; British Committee for Standards in Haematology. Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant*. Br J Haematol 2012;156:186-95. https://doi.org/10.1111/j.1365-2141.2011.08931.x
  15. Malfuson JV, Fagot T, Konopacki J, Souleau B, Cremades S, de Revel T. Which role for rituximab in hairy cell leukemia? Reflections on six cases. Acta Haematol. 2010;123:110-6. https://doi.org/10.1159/000270903
  16. Else M, Dearden CE, Matutes E, Forconi F, Lauria F, Ahmad H, et al. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leuk Lymphoma 2011;52:75-8. https://doi.org/10.3109/10428194.2011.568650
  17. Lauria F, Forconi F. Combination therapies to improve the long-term outcome in hairy cell leukemia. Leuk Lymphoma. 2009;50 Suppl 1:18-22. https://doi.org/10.3109/10428190903142273
  18. Forconi F. Hairy cell leukaemia: biological and clinical overview from immunogenetic insights. Hematol Oncol 2011;29:55-66. https://doi.org/10.1002/hon.975